Page 6 - Scientific Library

RNA-based CRISPR-CAS9 gene editing is a vector-free approach that is required for therapeutic perspectives. However, from a practical point of view, what appears as a major challenge to engineer

Tetramethylbenzidine (TMB) is a classic substrate for peroxidase activity that is used for microwell plate analysis such as an ELISA test. A quantitative color change from yellow to

In a previous post, I introduced the G-Series Mouse antibody arrays to profile up to 200 mouse proteins using a combination of 5 antibody arrays on glass slide. This new Mouse L2 L-Series

In a previous post, I introduced Sekisui Xenotech's Research Biobank, which is based on rejections from liver transplantation as opposed to post-mortem tissues, thus offering a guarantee

High density antibody arrays represent powerful technologies which have opened a new era in functional proteomics. However, when faced with a large magnitude of array data, you must apply comprehensive

I just want to briefly outline in this post the power of antibody microarray when it comes to time and cost saving as well as versatility. Whether you want to do multiple profiling or

Tropical and vector-borne diseases account for more than 17% of all infectious diseases, causing more than 1 million deaths annually. Recognizing infected patients early in their clinical course is critical

When it comes to proteomics and broad protein profiling (and/or quantification), two main technologies come to mind: Mass Spectrometry and Antibody Arrays. Rather than opposing each other,

Thanks to its capability to recruit the natural protein degradation system of a cell, PROTACs (PROteolysis TArgeting Chimera) appears as a very promising

Multiplex protein assays allow multiple targets quantification in a single sample, a bit like performing up to 40 different ELISAs in one go. Outsourcing Multiplex Protein Quantification projects

For all species, classes or size (FL vs. fragments)

Whatever the type of antibody production (hybridoma or recombinant protein production

In new drug development pipelines, there is an increasing trend to switch from "small" to "large" molecules (also known as biologics). While the FDA guidance was quite specific with their recommendations